Merck & Co Valuation Sheet

COMPARABLE VALUATION SHEET Merck is valued at a price to earnings (P/E) multiple of 13.5x, and is trading at a 10% discount to the S&P 500 Index's P/E. The stock is also trading at a 53% discount to the S&P Pharmaceuticals Index. It is the cheapest stock among competitors if their comparable P/E valuations are considered. Merck Johnson & Pfizer Eli Lilly Johnson Market Cap $138.3bn $263.35bn $210.99bn $56.95bn Revenue $46.21bn $69.99bn $58.09bn $22.6bn EV/EBITDA 8.46x 9.93x 7.8x 8.24x P/E forward 13.5x 15.94x 13.87x 18.22x PEG 4.54 2.52 3.65 101.87 Gross Margin 65% 67.8% 81% 78.7% Price/Sales 3.16x 3.35x 3.7x 2.88x Price/Book 2.94x 3.46x 2.38x 3.37x SOURCES: Company Data, SEC filings, Bloomberg Professional Services BIDNESS Etc. DISCLAIMER: Bidness Etc(TM) and related marks are owned by Bidness Etc. Any other trademarks appearing on this website are the property of their respective owners, and are not used to indicate the origin of goods or services offered or provided by Bidness Etc herein or to suggest approval for or affiliation with Bidness Etc. Share Price at Different Multiples Forecast EPS (NTM) $3.68 $59.7 $58.9 $55.6 $50 Price at S&P 500 Price at SPDR Price at Price at Competitors' Average P/E Multiple 16.22x Historical 5yr Average P/E Multiple Pharmaceuticals P/E ETF (XPH) P/E Multiple 16х Multiple 15.1x 13.6x SOURCES: Company Data, SEC filings, Bloomberg Professional Services BIDNESS Etc. DISCLAIMER: Bidness Etc(TM) and related marks are owned by Bidness Etc. Any other trademarks appearing on this website are the property of their respective owners, and are not used to indicate the origin of goods or services offered or provided by Bidness Etc herein or to suggest approval for or affiliation with Bidness Etc.